Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00488423 · ClinicalTrials.gov registry record · Phase 1

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

A Phase 1 study of Diabetes and Gastric Bypass, sponsored by The Cleveland Clinic.

Completed
Registry status
Phase 1
Development phase
21
Enrollment target
1
Study location

NCT00488423: Completed Phase 1 study of Diabetes and Gastric Bypass, sponsored by The Cleveland Clinic.

NCT00488423 is a Phase 1 study of Diabetes and Gastric Bypass that has completed, run by The Cleveland Clinic. The registered enrollment target is 21 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00488423, a Phase 1 study of Diabetes and Gastric Bypass, has completed, sponsored by The Cleveland Clinic.

COMPLETED
Registry status
Phase 1
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

MIDAS involves an assessment of glucose levels obtained before and after bariatric surgery. There are two different procedural tests involved; an oral glucose tolerance test (mixed meal) and a hyperglycemic clamp test. Two tests are performed preoperatively and five more are performed postoperatively for a one year period. The associated labwork drawn with the mixed meal and clamp tests are demonstrating changes in glucose, insulin and gut hormone levels.

Conditions Studied

Interventions

  • PROCEDURE Mixed Meal Tolerance test, Hyperglycemic clamp

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2006-11
Est. Completion 2008-11
Phase Phase 1
The Cleveland Clinic

688 total trials

What the finished NCT00488423 record still lists

NCT00488423 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Mixed Meal Tolerance test, Hyperglycemic clamp is the first listed.

NCT00488423 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT00488423 about?

NCT00488423 is a clinical study titled "Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery". MIDAS involves an assessment of glucose levels obtained before and after bariatric surgery. There are two different procedural tests involved; an oral glucose tolerance test (mixed meal) and a hyperglycemic clamp test. Two tests are performed preoperatively and five more are performed postoperativel...

What is the current status of trial NCT00488423?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2006-11. Estimated completion is 2008-11.

What conditions does trial NCT00488423 study?

This clinical trial studies the following conditions: Diabetes, Gastric Bypass.

What interventions are being tested in trial NCT00488423?

The interventions under investigation include: Mixed Meal Tolerance test, Hyperglycemic clamp (PROCEDURE).

Who is sponsoring clinical trial NCT00488423?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00488423 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00488423's enrollment target sits among peer trials

21 304th of 338 higher than 35 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00488423, the US trial registry maintained by the National Library of Medicine. NCT00488423 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.